×
Mannatech EBITDA 2010-2025 | MTEX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Mannatech ebitda from 2010 to 2025. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
View More
Mannatech EBITDA 2010-2025 | MTEX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Mannatech ebitda from 2010 to 2025. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Related Stocks
Company Name
Market
Cap
Chugai Pharmaceutical (CHGCY)
$70B
Zoetis (ZTS)
$68.3B
Takeda Pharmaceutical (TAK)
$47.7B
Daiichi Sankyo, - (DSNKY)
$47.6B
BeOne Medicines - (ONC)
$35.2B
Sandoz Group AG (SDZNY)
$26.1B
Summit Therapeutics (SMMT)
$19.8B
Merck (MKKGY)
$17.1B
Shionogi (SGIOY)
$15.2B
United Therapeutics (UTHR)
$14.1B
Neurocrine Biosciences (NBIX)
$13.2B
Orion OYJ (ORINY)
$10.8B
IPSEN (IPSEY)
$10.6B
Eisai (ESAIY)
$9.2B
Madrigal Pharmaceuticals (MDGL)
$8.2B
Corcept Therapeutics (CORT)
$7.6B
Grifols, S.A (GRFS)
$7.4B
Ionis Pharmaceuticals (IONS)
$7B
Stevanato Group S.p.A (STVN)
$6.9B
Hikma Pharmaceuticals Plc (HKMPF)
$5.3B
Ono Pharmaceutical (OPHLF)
$5.1B
Soleno Therapeutics (SLNO)
$3.8B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$3B
Crinetics Pharmaceuticals (CRNX)
$2.9B
NewAmsterdam Pharma (NAMS)
$2.8B
Hypermarcas (HYPMY)
$2.7B
Catalyst Pharmaceuticals (CPRX)
$2.5B
Centessa Pharmaceuticals (CNTA)
$2.4B
Ocular Therapeutix (OCUL)
$2.2B
Endo (NDOI)
$1.8B